Dermatology

>

Latest News

Corticosteroid Phobia among Individuals with Chronic Hand Eczema: Daily Dose / image credit: ©New Africa/AdobeStock
Corticosteroid Phobia among Individuals with Chronic Hand Eczema: Daily Dose

September 17th 2024

Your daily dose of the clinical news you may have missed.

Lilly Announces FDA Approval for Lebrikizumab-lbkz of Moderate to Severe Atopic Dermatitis image credit Courtesy of Lilly
Lilly Announces FDA Approval of Lebrikizumab-lbkz for Moderate to Severe Atopic Dermatitis

September 16th 2024

How to Define an Atopic Dermatitis Flare: Survey Seeks New Patient Consensus / image credit eczema:©Ityuan/stock.adobe.com
How to Define an Atopic Dermatitis Flare: Survey Seeks New Patient Consensus

September 12th 2024

Lebrikizumab Therapy Improved QoL, Mental Health Outcomes in Patients with Atopic Dermatitis / Image credit: ©Dragana Gordic/AdobeStock
Lebrikizumab Therapy Improved QoL, Mental Health Outcomes in Patients with Atopic Dermatitis

September 10th 2024

Tralokinumab May be Beneficial for Atopic Dermatitis Treatment in Special Patient Populations / Image credit: ©InfiniteStudio/AdobeStock
Tralokinumab May be Beneficial for Atopic Dermatitis Treatment in Special Patient Populations

September 9th 2024

Latest CME Events & Activities

Advances In™: Aligning Pathology and Oncology Efforts in the Community to Improve NSCLC Care

View More

Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

View More

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

October 16, 2024

Register Now!

Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)

View More

Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia

View More

Dermalorian™ Webinar Series on Moderate to Severe Atopic Dermatitis

November 21, 2024 - December 5, 2024

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

February 8, 2025

View More

Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis

View More

Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making

View More

Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma

View More

Community Practice Connections™: 20th Annual International Symposium on Melanoma and Other Cutaneous Malignancies

View More

Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis

View More

Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis

View More

Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color

View More

More News

© 2024 MJH Life Sciences

All rights reserved.